How do you incorporate deucravacitinib relative to biologics in patients with peripheral psoriatic arthritis and significant psoriasis?

How do you sequence deucravacitinib relative to biologics in patients with peripheral PsA and significant psoriasis?

• Routinely offer it before biologics
• Offer it before biologics only when oral therapy is preferred
• Reserve it until one biologic has failed or was not tolerated
• Reserve it until multiple biologics have failed or were not tolerated
• Do not currently use it for PsA
• Other